Hines, Dionne M <br/><br/>
Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.  [electronic resource] 

 -  Vascular health and risk management  2018 
 - 409-418 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1178-2048 
<br/><br/><label>Standard No.: </label>10.2147/VHRM.S180496  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administrative Claims, Healthcare<br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Anticholesteremic Agents--administration & dosage<br/>Atherosclerosis--blood<br/>Biomarkers--blood<br/>Cholesterol, LDL--blood<br/>Databases, Factual<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Formularies as Topic<br/>Humans<br/>Hyperlipoproteinemia Type II--blood<br/>Male<br/>Medicare--trends<br/>Middle Aged<br/>PCSK9 Inhibitors<br/>Practice Patterns, Physicians'--trends<br/>Proprotein Convertase 9--metabolism<br/>Retrospective Studies<br/>Serine Proteinase Inhibitors--administration & dosage<br/>Time Factors<br/>Treatment Outcome<br/>United States<br/>Young Adult